VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: Transthyretin precursor as a potential biomarker

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Saminathan, Ramasamy ^a   Bai, Jing ^b   Sadrolodabaee, Laleh ^b   Karthik, Govindasamy Muralidharan ^a   Singh, Onkar ^a   Subramaniyan, Koilan ^a   Ching, Chi Bun ^b   Chen, Wei Ning ^b   Chowbay, Balram ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b Nanyang Technological University   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 6; MULTIPROTEIN COMPLEX; PREALBUMIN; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; COHORT ANALYSIS; GENETICS; LIVER; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

ANTICOAGULANTS; BIOLOGICAL MARKERS; CELL LINE, TUMOR; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-6; LIVER; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PREALBUMIN; PROTEOMICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; WARFARIN;

EID: 78650781729     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015064     Document Type: Article

References (37)

1. Anand SS, Yusuf S (1999) Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. Journal of the American Medical Association 282: 2058-2067.
2. Smith P, Arnesen H, Holme I (1990) The effect of warfarin on mortality and reinfarction after myocardial infarction. New England Journal of Medicine 323: 147-152.
3. Beyth RJ, Milligan PE, Gage BF (2002) Risk factors for bleeding in patients taking coumarins. Current hematology reports 1: 41-49.
4. Wells PS, Holbrook AM, Crowther NR, Hirsh J (1994) Interactions of warfarin with drugs and food. Annals of Internal Medicine 121: 676-683.
5. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, et al. (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology and Therapeutics 75: 204-212.
6. Absher RK, Moore ME, Parker MH, Rivera-Miranda G, Perreault MM (2002) Patient-specific factors predictive of warfarin dosage requirements. Annals of Pharmacotherapy 36: 1512-1517.
7. Gan GG, Teh A, Goh KY, Chong HT, Pang KW (2003) Racial background is a determinant factor in the maintenance dosage of warfarin. International Journal of Hematology 78: 84-86.
8. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, et al. (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology and Therapeutics 72: 702-710.
9. Liu L, Liu J, Dai S, Wang X, Wu S, et al. (2007) Reduced transthyretin expression in sera of lung cancer. Cancer Science 98: 1617-1624.
10. Limdi NA, Veenstra DL (2008) Warfarin pharmacogenetics. Pharmacotherapy 28: 1084-1097.
11. Kamali F, Wynne H. Pharmacogenetics of warfarin. Annual Review of Medicine 63-75.
12. Breckenridge A, Orme M, Wesseling H (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clinical Pharmacology and Therapeutics 15: 424-430.
13. Takahashi H, Echizen H (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clinical Pharmacokinetics 40: 587-603.
14. Lee CR, Goldstein JA, Pieper JA (2002) Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 12: 251-263.
15. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, et al. (2001) Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. British Journal of Clinical Pharmacology 52: 447-450.
16. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, et al. (2001) Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. British Journal of Clinical Pharmacology 51: 277-280.
17. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, et al. (2004) Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clinical Pharmacology and Therapeutics 76: 210-219.
18. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96: 1816-1819.
19. Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717-719.
20. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, et al. (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427: 541-544.
21. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, HÃrtnagel K, et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427: 537-541.
22. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New England Journal of Medicine 352: 2285-2293.
23. Sandanaraj E, Lal S, Cheung YB, Xiang X, Kong MC, et al. (2009) VKORC1 diplotype-derived dosing model to explain variability in warfarin dose requirements in Asian patients. Drug Metabolism and Pharmacokinetics 24: 365-375.
24. Lal S, Sandanaraj E, Jada SR, Kong MC, Lee LH, et al. (2008) Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. British Journal of Clinical Pharmacology 65: 260-264.
25. Sui J, Zhang J, Tan TL, Ching CB, Chen WN (2008) Comparative proteomics analysis of vascular smooth muscle cells incubated with S-and R-Enantiomers of atenolol using iTRAQ-coupled two-dimensional LC-MS/MS. Molecular and Cellular Proteomics 7: 1007-1018.
26. Sui J, Tuan LT, Zhang J, Chi BC, Wei NC (2007) iTRAQ-coupled 2D LC-MS/ MS analysis on protein profile in vascular smooth muscle cells incubated with Sand R-enantiomers of propranolol: possible role of metabolic enzymes involved in cellular anabolism and antioxidant activity. Journal of Proteome Research 6: 1643-1651.
27. Zhang J, Sui J, Chi BC, Wei NC (2008) Protein profile in neuroblastoma cells incubated with S-and R-enantiomers of ibuprofen by iTRAQ-coupled 2-D LCMS/ MS analysis: Possible action of induced proteins on Alzheimer's disease. Proteomics 8: 1595-1607.
28. Citarella F, Felici A, Brouwer M, Wagstaff J, Fantoni A, et al. (1997) Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 90: 1501-1507.
29. Kater AP, Peppelenbosch MP, Brandjes DPM, Lumbantobing M (2002) Dichotomal effect of the coumadin derivative warfarin on inflammatory signal transduction. Clinical and Diagnostic Laboratory Immunology 9: 1396-1397.
30. Sandanaraj E, Lal S, Cheung YB, Xiang XQ, Kong MC, et al. (2009) VKORC1 Diplotype-Derived Dosing Model to Explain Variability in Warfarin Dose Requirements in Asian Patients. Drug Metabolism and Pharmacokinetics 24: 365-375.
31. Purkey HE, Dorrell MI, Kelly JW (2001) Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proceedings of the National Academy of Sciences of the United States of America 98: 5566-5571.
32. Palha JA (2002) Transthyretin as a thyroid hormone carrier: Function revisited. Clinical Chemistry and Laboratory Medicine 40: 1292-1300.
33. Feldt-Rasmussen U, Rasmussen AK (2007) Thyroid hormone transport and actions; Krassas GE, Rivkees SA, Kiess W, eds. Basel: Karger.
34. Buxbaum JN, Reixach N (2009) Transthyretin: the servant of many masters. Cellular and Molecular Life Sciences 66: 3095-3101.
35. Bartalena L, Farsetti A, Flink IL, Robbins J (1992) Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Molecular Endocrinology 6: 935-942.
36. Maclean PS, Tait RC, Rumley A, McMahon AD, Lowe GD (2003) Anticoagulation with warfarin downregulates inflammation. Journal of Thrombosis and Haemostasis 1: 1838-1839.
37. Kurohara M, Yasuda H, Moriyama H, Nakayama M, Sakata M, et al. (2008) Low-dose Warfarin Functions as an Immunomodulator to Prevent Cyclophosphamide-induced NOD Diabetes. Kobe J Med Sci 51: E1-E13.